LNWTC
ALNY icon

Laird Norton Wetherby Trust Company’s Alnylam Pharmaceuticals ALNY Stock Holding History

Laird Norton Wetherby Trust Company’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$993K Sell
3,300
-207
-6% -$62.4K 0.02% 512
2026
Q1 		$1.16M Buy
3,507
+6
+0.2% +$2.04K 0.03% 449
2025
Q4 		$1.39M Buy
+3,501
New +$1.55M 0.03% 411

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Laird Norton Wetherby Trust Company's ALNY Position: Q2 2026 in Review

Laird Norton Wetherby Trust Company reduced its Alnylam Pharmaceuticals (ALNY) stake by 5.9% in Q2 2026, selling an estimated $62.4K and leaving 3,300 shares worth $993K. The position accounts for 0.02% of the portfolio, ranked #512.

Laird Norton Wetherby Trust Company first reported a position in ALNY in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.39M in Q4 2025. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Laird Norton Wetherby Trust Company held 3,300 shares of Alnylam Pharmaceuticals worth $993K as of Q2 2026.
  • Laird Norton Wetherby Trust Company sold 207 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $62.4K.
  • Alnylam Pharmaceuticals made up 0.02% of Laird Norton Wetherby Trust Company's portfolio in Q2 2026, its #512 holding.
  • Laird Norton Wetherby Trust Company first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Laird Norton Wetherby Trust Company's Alnylam Pharmaceuticals position peaked at $1.39M in Q4 2025.
  • 788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Laird Norton Wetherby Trust Company's 13F filing for Q2 2026, filed 14 Aug 2026.